Summary
Boston Scientific Corporation reported a net loss of $13 million, or $0.01 per share, for the first quarter of 2009, a significant shift from the $322 million net income, or $0.21 per share, reported in the same period of the prior year. This decline was largely driven by substantial litigation-related charges, which amounted to $287 million (pre-tax). Despite the net loss, the company's net sales saw a modest increase of 2% on a constant currency basis, reaching $2.01 billion. This performance was supported by growth in its Cardiac Rhythm Management (CRM) and Endosurgery segments, particularly in the U.S. market, and a stable performance in coronary stents. The company continues to navigate significant legal challenges, most notably a $237 million charge related to a patent infringement ruling against Johnson & Johnson. Restructuring charges and ongoing litigation also weighed on profitability. However, management highlighted progress in other areas, including the development of next-generation products and a focus on core businesses, aiming to strengthen the company's position for sustainable, profitable growth.
Financial Highlights
26 data points| Revenue | $2.01B |
| Cost of Revenue | $607.00M |
| Gross Profit | $1.40B |
| SG&A Expenses | $651.00M |
| Operating Expenses | $1.39B |
| Operating Income | $11.00M |
| Interest Expense | $102.00M |
| Net Income | -$13.00M |
| EPS (Basic) | $-0.01 |
| EPS (Diluted) | $-0.01 |
| Shares Outstanding (Basic) | 1.50B |
| Shares Outstanding (Diluted) | 1.50B |
Key Highlights
- 1Net loss of $13 million ($0.01/share) in Q1 2009, compared to a net income of $322 million ($0.21/share) in Q1 2008.
- 2Net sales of $2.01 billion, a 2% decrease as reported but a 2% increase on a constant currency basis compared to Q1 2008.
- 3Significant litigation-related charges of $287 million pre-tax in Q1 2009, including a $237 million charge related to a patent infringement case with Johnson & Johnson.
- 4Continued restructuring efforts with $23 million in restructuring charges in Q1 2009.
- 5Cardiac Rhythm Management (CRM) segment showed strength with U.S. sales up 11% year-over-year, driven by new product launches.
- 6Coronary stent sales remained stable, with the company maintaining a leading market share in drug-eluting stents.
- 7Company's cash position decreased significantly to $897 million from $1,641 million at the end of the prior year, primarily due to debt repayments and acquisition-related payments.